Roche: Tecentriq combo misses endpoint in colorectal cancer
(CercleFinance.com) - Roche said a Phase III clinical trial evaluating the combination of two cancer drugs did not meet its main target in the treatment of colorectal cancer.
The study evaluating the combination of Tecentriq and Cotellic did not meet its primary endpoint of overall survival compared to Bayer's regorafenib, the Swiss drugmaker said.
The study focused on people with difficult-to-treat, locally advanced or metastatic colorectal cancer whose disease progressed or who were intolerant to at least two systemic chemotherapy regimens.
Zurich-listed Roche was still up 0.2% after the news.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The study evaluating the combination of Tecentriq and Cotellic did not meet its primary endpoint of overall survival compared to Bayer's regorafenib, the Swiss drugmaker said.
The study focused on people with difficult-to-treat, locally advanced or metastatic colorectal cancer whose disease progressed or who were intolerant to at least two systemic chemotherapy regimens.
Zurich-listed Roche was still up 0.2% after the news.
Copyright (c) 2018 CercleFinance.com. All rights reserved.